Our Case Studies

Gain 12x higher accuracy, intuitive bench-ready tools, and technology validated in prospective in-vivo studies.

Deepflare achieves a manufacturable vaccine candidate with a more potent immune response on the very first try.

Deepflare — 3 min read — 23.10.2025

Deepflare achieves a manufacturable vaccine candidate with a more potent immune response on the very first try.

Our partner, Hawaii Biotech, took the notoriously difficult Zika Envelope protein and, with the Deepflare platform, designed mutations we predicted would boost its immunogenicity.

Read now
Deepflare achieves 3x higher hit-rate than netMHCPan in Progeneer's in vivo study of cancer vaccine

Deepflare — 3 min read — 23.10.2025

Deepflare achieves 3x higher hit-rate than netMHCPan in Progeneer's in vivo study of cancer vaccine

Bridging the Gap Between Predicted Antigenicity and In Vivo Efficacy of Cancer Vaccines

Read now
Deepflare achieves 100% success in vitro protein expression. Is it a new level of vaccine design?

Deepflare — 3 min read — 23.10.2025

Deepflare achieves 100% success in vitro protein expression. Is it a new level of vaccine design?

In a recent collaboration with the leading French Biotech company Osivax, Deepflare demonstrated that for the most challenging viral vaccines, even Nobel-winning AI models like RFdiffusion can be of no use.

Read now

Get started for
free today

Gain 12x higher accuracy, intuitive bench-ready tools, and technology validated in prospective in-vivo studies.

Try for free